Advances in the treatment of depression

E. Hollander

doi:10.1017/s1092852900011962

Advances in the treatment of depression

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	13
Number of pages	1
Journal	CNS spectrums
Volume	4
Issue number	7
DOIs	https://doi.org/10.1017/s1092852900011962
State	Published - 1999
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1017/s1092852900011962

Cite this

@article{831437c075994cf983b5a679a6f9729e,

title = "Advances in the treatment of depression",

author = "E. Hollander",

note = "Funding Information: This work was supported by the National Institutes of Health (NIH)/National Institute of Mental Health (P50 MH 058922, R01 MH 042088, and U19 MH 069056) (to C.B.N.) and by the Emory Mentored Clinical Research Scholars Program through a grant from NIH/National Center for Research Resources (K12 RR 017643) (to P.E.H.). Funding Information: Disclosures: C.B.N. has received grants from the American Foundation for Suicide Prevention (AFSP); AstraZeneca; Bristol-Myers-Squibb; Forest Laboratories; Janssen Pharmaceutica; National Alliance for Research in Schizophrenia and Depression (NARSAD); National Institute of Mental Health (NIMH); Pfizer Pharmaceuticals; Stanley Foundation; National Alliance for the Mentally Ill (NAMI); and Wyeth-Ayerst. He is a consultant for Abbott Laboratories, Acadia Pharmaceuticals, Bristol-Myers-Squibb, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Otsuka, Pfizer Pharmaceuticals, Quintiles, and Wyeth-Ayerst. He is on the Speakers Bureau for Abbott Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer Pharmaceuticals. He owns stock in Corcept, Cypress Biosciences, and Acadia Pharmaceuticals. He is on the Board of Directors for AFSP, American Psychiatric Institute for Research and Education (APIRE), George West Mental Health Foundation, Novadel Pharma, and National Foundation for Mental Health (NFMH). He has patents for “Method and devices for transdermal delivery of lithium (US 6375,990 B1)” and “Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001).” He has equity in Reevax, BMC-JR LLC, and CeNeRx. P.E.H. has received grants from the American Federation for Aging Research (AFAR), Neuronetics, Inc., and the National Center for Research Resources. ",

year = "1999",

doi = "10.1017/s1092852900011962",

language = "English (US)",

volume = "4",

pages = "13",

journal = "CNS Spectrums",

issn = "1092-8529",

publisher = "MBL Communications",

number = "7",

}

TY - JOUR

T1 - Advances in the treatment of depression

AU - Hollander, E.

N1 - Funding Information: This work was supported by the National Institutes of Health (NIH)/National Institute of Mental Health (P50 MH 058922, R01 MH 042088, and U19 MH 069056) (to C.B.N.) and by the Emory Mentored Clinical Research Scholars Program through a grant from NIH/National Center for Research Resources (K12 RR 017643) (to P.E.H.). Funding Information: Disclosures: C.B.N. has received grants from the American Foundation for Suicide Prevention (AFSP); AstraZeneca; Bristol-Myers-Squibb; Forest Laboratories; Janssen Pharmaceutica; National Alliance for Research in Schizophrenia and Depression (NARSAD); National Institute of Mental Health (NIMH); Pfizer Pharmaceuticals; Stanley Foundation; National Alliance for the Mentally Ill (NAMI); and Wyeth-Ayerst. He is a consultant for Abbott Laboratories, Acadia Pharmaceuticals, Bristol-Myers-Squibb, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Otsuka, Pfizer Pharmaceuticals, Quintiles, and Wyeth-Ayerst. He is on the Speakers Bureau for Abbott Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer Pharmaceuticals. He owns stock in Corcept, Cypress Biosciences, and Acadia Pharmaceuticals. He is on the Board of Directors for AFSP, American Psychiatric Institute for Research and Education (APIRE), George West Mental Health Foundation, Novadel Pharma, and National Foundation for Mental Health (NFMH). He has patents for “Method and devices for transdermal delivery of lithium (US 6375,990 B1)” and “Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001).” He has equity in Reevax, BMC-JR LLC, and CeNeRx. P.E.H. has received grants from the American Federation for Aging Research (AFAR), Neuronetics, Inc., and the National Center for Research Resources.

PY - 1999

Y1 - 1999

UR - http://www.scopus.com/inward/record.url?scp=0032792906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032792906&partnerID=8YFLogxK

U2 - 10.1017/s1092852900011962

DO - 10.1017/s1092852900011962

M3 - Comment/debate

AN - SCOPUS:0032792906

VL - 4

SP - 13

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 7

ER -